What to Expect in 2025 in 340B, TPA and Infusion Therapy
A practical outlook on 2025 policy and operational shifts affecting 340B programs, third-party administration, infusion services, and pharmacy strategy for FQHCs.
Remy Healthcare Team
6 min read · January 30, 2025
Healthcare leaders do not need a perfect forecast to prepare for 2025. They need a working view of where policy, reimbursement, and operational pressure are likely to land. For FQHCs and safety-net providers, that means paying close attention to 340B oversight, the evolution of third-party administration, and the continued growth of outpatient infusion care.
The organizations that adapt fastest are usually the ones that prepare before the final rule, not after it.
Key Takeaways
- 340B pressure is likely to keep increasing around documentation, transparency, and operational discipline.
- TPA strategy is becoming more technology-driven, especially in claims, compliance, and workflow automation.
- Outpatient infusion demand continues to grow, but reimbursement and staffing pressure will make operating efficiency more important.
- FQHCs that invest early in data visibility and workflow design will be better positioned than organizations that react late.
340B is heading into a more demanding operating environment
The 340B program remains strategically essential for covered entities, but the direction of travel is clear: more scrutiny, more documentation pressure, and less tolerance for operational ambiguity.
Even when policy details move slowly, providers should plan for a world where:
- eligibility documentation is reviewed more carefully
- manufacturer restrictions and disputes continue shaping workflow
- audit readiness matters more than policy interpretation alone
- claims, inventory, and patient qualification data need to be easier to defend
For many teams, the biggest change is not the rule itself. It is the amount of operational rigor required to stay comfortable inside the rule.
Compliance maturity will separate strong programs from stressed programs
Some organizations will experience 2025 as disruption. Others will experience it as validation because they already built cleaner systems.
That difference usually comes down to whether the program has:
- dependable patient qualification logic
- auditable documentation trails
- timely reporting and reconciliation
- clear ownership of compliance operations
If your 340B program still depends on manual workarounds, inconsistent documentation, or vendor black boxes, 2025 is more likely to feel expensive than strategic.
TPA strategy is becoming a technology decision
Third-party administration used to be framed mostly as an outsourcing choice. Increasingly, it is a systems decision.
The best TPA environments are using automation and analytics to improve:
- claims throughput
- denial prevention
- eligibility verification
- compliance flagging
- reporting speed
That matters because healthcare operators are under pressure to do more with leaner teams. A TPA model that cannot improve visibility and consistency will start to feel dated quickly.
Where AI and automation are likely to matter most
Not every workflow needs artificial intelligence. But several administrative pain points are already strong candidates for automation:
- claims review and exception routing
- prior authorization prep
- inventory and demand forecasting
- discrepancy detection in 340B-related workflows
- documentation support and reporting prep
The value of these tools is not novelty. It is speed, consistency, and lower administrative drag.
Infusion care will keep shifting toward more accessible delivery models
Infusion demand is still growing, and more of that care is moving into lower-cost, outpatient-friendly settings. For many providers, this creates both opportunity and pressure.
On one side:
- more patients need ongoing infused therapies
- local access remains uneven
- outpatient convenience is increasingly valuable
On the other:
- reimbursement can tighten
- staffing can be hard to scale
- operational complexity increases as volume rises
That means 2025 is likely to reward providers that treat infusion as an operational model, not just a service add-on.
What this means for FQHCs
For FQHCs, the convergence of 340B, TPA operations, and infusion growth creates a specific strategic question:
How do you preserve compliance and access while also building a financially sustainable care model?
In practice, the strongest answer usually includes:
- tighter pharmacy and claims visibility
- better use of analytics
- clearer site-of-care strategy
- stronger care continuity for infused therapies
- more deliberate use of 340B advantages
A practical 2025 readiness checklist
If you are preparing your organization now, focus on the following:
- Audit the manual parts of your 340B process.
- Review whether your TPA model improves visibility or just moves work elsewhere.
- Identify infused therapies that may be better managed through a stronger site-of-care strategy.
- Tighten reporting and documentation before oversight pressure increases.
- Build a leadership view of pharmacy, reimbursement, and infusion economics together.
The organizations that will be strongest in 2025
They will not necessarily be the biggest. They will be the clearest.
They will know:
- where their margin leaks out
- where compliance risk sits
- where patients encounter care friction
- where technology can remove repetitive administrative burden
That clarity is what turns policy uncertainty into a manageable operating problem.
2025 should be treated as a systems year
The next wave of advantage will not come from chasing headlines. It will come from building better systems around the work you already do: cleaner 340B operations, smarter TPA infrastructure, and more efficient infusion delivery.
For healthcare leaders, that is the real opportunity.
Frequently Asked Questions
- What is the biggest 340B risk heading into 2025?
- The biggest risk is not one isolated rule change. It is operating a 340B program without strong documentation, clean data flow, and clear compliance ownership while oversight expectations continue to increase.
- How is TPA strategy changing in 2025?
- TPA strategy is becoming more dependent on workflow automation, analytics, and real-time visibility. Providers increasingly need administrative partners and systems that reduce friction instead of simply taking tasks off their plate.
- Why does infusion strategy belong in 2025 planning?
- Because outpatient infusion demand continues to grow and site-of-care decisions directly affect patient access, reimbursement, staffing pressure, and 340B economics.
- What should FQHC leaders focus on first?
- Start with workflow maturity: documentation, reporting, claims visibility, and site-of-care economics. Those foundations make policy change easier to absorb.
Need help preparing for the next policy wave?
We help FQHCs and healthcare operators translate 340B, TPA, and infusion complexity into practical operating plans that are easier to manage and defend.
Schedule a strategy call
Written by
Remy Healthcare Team
340B & FQHC Specialists
The Remy team advises FQHCs and 340B covered entities on program management, infusion operations, and revenue optimization.
